Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acadia Pharmaceuticals Inc.

www.acadia-pharm.com

Latest From Acadia Pharmaceuticals Inc.

Acadia’s Nuplazid Shows Nearly Three-Fold Reduction In Psychosis Relapse

Data presented at the CTAD meeting for pimavanserin in dementia-related psychosis will support an sNDA filing in 2020 for an approval that could broaden the drug’s market exponentially.

Clinical Trials Neurology

Acadia Revives Nuplazid’s Chances In Schizophrenia With Negative Symptom Data

After a Phase III failure in refractory schizophrenia, Acadia has Phase II data showing efficacy in negative symptoms of the disease, an unmet need. It plans a pivotal study in 2020.

Life Cycle Management Clinical Trials

Finance Watch: Two New IPOs – IGM In the US, Henlius In Hong Kong – Gross Nearly $600m

Public Company Edition: IGM raised $175m to advance its IgM antibodies and Henlius brought in $410m for its novel drug and biosimilar platforms. Also, Acadia follow-on brings in $250m, PTC sells $350m worth of stock and debt, and Karyopharm royalty deal totals $150m.

Financing Business Strategies

Acadia Claims Success For Nuplazid In A Broader Psychosis Indication

The company expects to file pimavanserin for the treatment of dementia-related psychosis in 2020, based on the results of a single positive Phase III trial.

Neurology Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Acadia Pharmaceuticals Inc.
  • Senior Management
  • Stephen Davis, CEO
    Elena Ridloff, EVP, CFO
    Michael J Yang, EVP, Chief Commercial Officer
    Serge Stankovic, MD, Pres.
    Daryl DeKarske, SVP, Global Head, Reg. Affairs
    Charmaine Lykins, SVP, Mktg.
    Bob Mischler, SVP, Strategy & Tech. Operations
    Eliseo Salinas, MD, MSc, SVP, CSO & Head, External Innovation
    Ponni Subbiah, MD, CMO & SVP, Global Head, Medical Affairs
  • Contact Info
  • Acadia Pharmaceuticals Inc.
    Phone: (858) 558-2871
    3611 Valley Centre Dr.
    Ste. 300
    San Diego, CA 92130
    USA
UsernamePublicRestriction

Register